Analysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding (OtherRHHBY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding (RHHBY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Roche Holding (RHHBY)
TD Cowen analyst Steve Scala maintained a Hold rating on Roche Holding yesterday and set a price target of $67.00. The company’s shares closed last Thursday at $51.86.
According to TipRanks.com, Scala is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding with a $54.60 average price target.
See the top stocks recommended by analysts >>
Praxis Precision Medicines (PRAX)
In a report released yesterday, Benjamin Burnett from Wells Fargo maintained a Hold rating on Praxis Precision Medicines, with a price target of $305.00. The company’s shares closed last Thursday at $329.60.
According to TipRanks.com, Burnett is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Praxis Precision Medicines with a $625.31 average price target, an 84.1% upside from current levels. In a report issued on April 15, TipRanks – xAI also reiterated a Hold rating on the stock with a $330.00 price target.
SAB Biotherapeutics (SABS)
In a report released yesterday, Yatin Suneja from Guggenheim maintained a Buy rating on SAB Biotherapeutics, with a price target of $15.00. The company’s shares closed last Thursday at $3.80.
According to TipRanks.com, Suneja is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAB Biotherapeutics with a $11.67 average price target, which is a 192.5% upside from current levels. In a report issued on April 22, Craig-Hallum also maintained a Buy rating on the stock.
Read More on RHHBY:
Disclaimer & DisclosureReport an Issue
- Roche reports Q1 group sales CHF 14.7B vs. CHF 15.4B last year
- Roche expects increase in group sales in mid single digit range for FY26
- Genentech’s treatment of KRAS G12C-positive NSCLC granted FDA orphan designation
- Genetech says Phase III METEROID study of Enspryng meets primary endpoint
- Roche announces U.S. FDA accepted sBLA for Gazyva/Gazyvaro
